GlassScriptPhysician profile
Deborah Ushkow
NPI 1396716403
$7,575.36
in general payments reported to CMS, 2019-2025
27 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,790 · 2020: $1,243 · 2021: $1,566 · 2022: $278 · 2023: $1,253 · 2024: $97.34 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.44 |
| Education | $259.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,392.92 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.29 | 2019-2021 | |
| Mylan Specialty L.P. | $561.37 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $551.15 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $407.48 | 2019-2024 | Breztri, Fasenra |
| Philips North America LLC | $363.94 | 2019-2022 | |
| Genzyme Corporation | $356.37 | 2019-2023 | |
| Grifols USA, LLC | $244.28 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $235.23 | 2019-2020 | |
| Genentech USA, INC. | $207.30 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $204.69 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $192.95 | 2019-2020 | |
| Advanced Respiratory, INC | $184.28 | 2019-2021 | |
| Inspire Medical Systems, INC. | $154.88 | 2023 | Inspire |
| Pulmonx Corporation | $149.53 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $138.58 | 2019 | |
| Ethicon INC. | $124.99 | 2021 | |
| Circassia INC. | $113.23 | 2019-2020 | |
| Electromed, INC. | $60.84 | 2021 | |
| Pfizer INC. | $54.19 | 2019 | |
| Amgen INC. | $49.96 | 2022 | |
| Mallinckrodt Hospital Products INC. | $34.88 | 2021 | |
| Insmed, INC. | $31.94 | 2021 | |
| Merck Sharp & Dohme LLC | $26.56 | 2019 | |
| Covis Pharma Gmbh | $25.72 | 2020 | |
| Horizon Therapeutics Plc | $15.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Ushkow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.